Log in to MyACC
Key Points | Andexanet Alfa for Anticoagulant Reversal
This article reviews andexanet alfa for reversing the anticoagulant effects of apixaban or rivaroxaban.
Guidelines
JACC Journals on ACC.org
- JACC
- JACC: Advances
- JACC: Asia
- JACC: Basic to Translational Science
- JACC: CardioOncology
- JACC: Cardiovascular Imaging
- JACC: Cardiovascular Interventions
- JACC: Case Reports
- JACC: Clinical Electrophysiology
- JACC: Heart Failure
Membership
- Current Members
- Campaign for the Future
- Become a Member
- Renew Your Membership
- Member Benefits and Resources
- Member Sections
- Chapters
- ACC Member Directory
About ACC
Clinical Topics
- Acute Coronary Syndromes
- Anticoagulation Management
- Arrhythmias and Clinical EP
- Cardiac Surgery
- Cardio-Oncology
- Chronic Angina
- Congenital Heart Disease and Pediatric Cardiology
- COVID-19 Hub
- Diabetes and Cardiometabolic Disease
- Dyslipidemia
- Geriatric Cardiology
- Heart Failure and Cardiomyopathies
- Hypertriglyceridemia
- Invasive Cardiovascular Angiography and Intervention
- Noninvasive Imaging
- Pericardial Disease
- Prevention
- Pulmonary Hypertension and Venous Thromboembolism
- Sports and Exercise Cardiology
- Stable Ischemic Heart Disease
- Valvular Heart Disease
- Vascular Medicine
Latest in Cardiology
- Clinical Updates & Discoveries
- Advocacy & Policy
- Perspectives & Analysis
- Meeting Coverage
- ACC Member Publications
- ACC Podcasts
Education and Meetings
- Online Learning Catalog
- Understanding MOC
- Products and Resources
- Image and Slide Gallery
- Meetings
- Certificates and Certifications
- Annual Scientific Session
Tools and Practice Support
- JACC
- Quality Improvement for Institutions
- NCDR
- CardioSmart
- MedAxiom
- Accreditation Services
- Contact Us
Heart House
- 2400 N St. NW
- Washington, DC 20037
- Email: membercare@acc.org
